Print
Advertisement
Exposure to thalidomide analogs is associated with TP53 mutations in patients with therapy-related myeloid neoplasms.
Given the multitude of novel therapies recently approved, clinicians must consider how to best sequence the options.
CAR-T therapy leads to responses in most patients with aggressive B-cell lymphoma, but durable CRs only occur in a minority.
Thomas G. Martin, MD, and Saad Z. Usmani, MD, MBA, FACP, debate CAR-T vs bispecific antibodies for R/R MM.
Combining proteomic data with genetic risk-stratification data may help tailor therapy for pediatric AML.
Glofitamab is an investigational CD20×CD3 T-cell-engaging bispecific antibody.
Advertisement
Maintenance therapy strategies for AML have been investigated for decades, including single agents and combinations.
Chadi Nabhan, MD, MBA, FACP, hosts The HemOnc Pulse, a podcast from Blood Cancers Today and SOHO.
The FDA received a Biologics License Application for the use of talquetamab in patients with R/R multiple myeloma.
The U.S. Food and Drug Administration (FDA) has approved zanubrutinib for the treatment of CLL and SLL.
BCL2 inhibitors (eg, venetoclax) have clinical benefits for patients with CLL, but overcoming resistance remains a challenge.
Elranatamab was granted Breakthrough Therapy Designation by the U.S. FDA for relapsed/refractory multiple myeloma.
Jonathon Cohen, MD, discusses how he came to focus on lymphoma, as well as current research, pressing questions, and more.
Moxetumomab pasudotox will be discontinued from the market in the US in July 2023.
Jennifer R. Brown, MD, PhD, and Anthony Mato, MD, MSCE, debate combinations versus sequencing approaches in CLL.
Orelabrutinib has been approved by the Health Sciences Authority of Singapore for the treatment of adults with MCL.
The European Commission has approved zanubrutinib for the treatment of adults with chronic lymphocytic leukemia.
The U.S. FDA has accepted for review and filed the New Drug Application for motixafortide.
Survival outcomes are typically poor in patients with relapsed/refractory aggressive BCL who relapse after anti-CD19 CAR-T.
Lenalidomide plus rituximab is “an acceptable chemotherapy-free alternative” to rituximab plus chemo in patients with FL.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
670 Madison Ave.
Manalapan, NJ 07726